{
    "clinical_study": {
        "@rank": "157919", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "No Intervention", 
                "description": "Patients will receive only the Version 1 handout."
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Other", 
                "description": "Patients will receive the Version 1 handout, the Version 1 MP3, and acupressure bands."
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive the Version 2 handout, the Version 2 MP3, and acupressure bands."
            }
        ], 
        "brief_summary": {
            "textblock": "216 Chemotherapy-na\u00efve, female breast cancer patients about to begin chemotherapy and who\n      expect to have nausea, will be entered.  Participants will be randomized to one of three\n      study arms: Arm 1: Version 1 handout; Arm 2: Version 1 handout + Version 1 relaxation MP3 +\n      acupressure bands; Arm 3: Version 2 handout + Version 2 relaxation MP3 + acupressure bands.\n\n      Hypothesis:   Acupressure bands provided with the relaxation MP3 will be effective in\n      controlling chemotherapy-induced nausea"
        }, 
        "brief_title": "Alternative Approaches for Nausea Control", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Nausea", 
        "condition_browse": {
            "mesh_term": "Nausea"
        }, 
        "detailed_description": {
            "textblock": "Earlier research has shown that the effectiveness of acupressure bands in reducing nausea\n      could be enhanced by boosting patients' expectations of the bands' efficacy. The present\n      study seeks to confirm and extend these findings in a multi-site, 3-arm, randomized,\n      controlled study of 216 breast cancer patients beginning chemotherapy who expect to have\n      nausea.  All patients will receive a standardized antiemetic regimen.  Arm 1: Version 1 of\n      Handout; Arm 2: Version 1 of handout + Version 1 relaxation MP3 + acupressure bands; Arm 3:\n      Version 2 of handout + Version 2 of relaxation MP3 + acupressure bands.  The investigators\n      hypothesize that acupressure bands provided with the relaxation MP3 will be effective in\n      controlling chemotherapy-induced nausea. The two versions of the handout and MP3 are being\n      examined to determine what is the most effective way to deliver the intervention."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be female.\n\n          -  Have a diagnosis of breast cancer, any stage.\n\n          -  Be chemotherapy na\u00efve and about to begin her first course of chemotherapy.\n\n          -  Be scheduled to receive one of the following four common chemotherapy regimens with\n             the specified antiemetic regimen.  They are:\n\n               1. Chemotherapy regimen: Doxorubicin/cyclophosphamide. Antiemetic regimen:\n                  Aprepitant + palonosetron + dexamethasone on Day 1 and aprepitant +\n                  dexamethasone on Days 2 & 3.\n\n               2. Chemotherapy regimen: Doxorubicin/cyclophosphamide/docetaxel.  Antiemetic\n                  regimen: Aprepitant + palonosetron + dexamethasone on Day 1 and aprepitant +\n                  dexamethasone on Days 2 & 3.\n\n               3. Chemotherapy regimen: Docetaxel/carboplatin. Antiemetic regimen: Palonosetron on\n                  Day 1 + dexamethasone on Days 1, 2, & 3.\n\n               4. Chemotherapy regimen: Docetaxel/cyclophosphamide. Antiemetic regimen:\n                  Palonosetron on Day 1 + dexamethasone on Days 1, 2, & 3.\n\n        Note: Fosaprepitant will be allowed in place of aprepitant, and either granisetron or\n        ondansetron, on one or more days, will be allowed in place of palonosetron.\n\n          -  Have a response of  > 3 or greater on a question assessing expected nausea as\n             assessed on a 5-point Likert-scale anchored at one end by 1 = \"I am certain I WILL\n             NOT have this,\" and at the other end by 5 = \"I am certain I WILL have this.\"\n\n          -  Be able to read English (since the assessment materials are in printed format).\n\n          -  Be 18 years of age or older and give written informed consent.\n\n        Exclusion Criteria:\n\n          -  Have clinical evidence of lymphedema, current bowel obstruction, or symptomatic brain\n             metastases, as determined by their treating oncologist.\n\n          -  Be receiving concurrent radiotherapy or interferon."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "216", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695993", 
            "org_study_id": "UCCS1202", 
            "secondary_id": "R01AT007474-01A1"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 2", 
                    "Arm 3"
                ], 
                "description": "Bilateral acupressure wrist bands (Sea-Band International, England), given to patients in trial Arms 2 and 3, are widely available and inexpensive (under $6.00 a pair).", 
                "intervention_name": "Acupressure bands", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "The Version 1 handout has less information concerning the acupressure bands than the Version 2 handout.", 
                "intervention_name": "Version 1 handout", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.", 
                "intervention_name": "Version 1 MP3", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "description": "The Version 2 handout has more information concerning the acupressure bands than the Version 1 handout.", 
                "intervention_name": "Version 2 handout", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "description": "Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. The MP3 (for subjects randomized to Arm 3) has some additional information in it regarding relaxation.", 
                "intervention_name": "Version 2 MP3", 
                "intervention_type": "Behavioral"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nausea", 
            "Quality of life", 
            "Chemotherapy", 
            "Expectancy"
        ], 
        "lastchanged_date": "January 6, 2014", 
        "location": [
            {
                "contact": {
                    "email": "cab21@healthresearch.org", 
                    "last_name": "Mary Lynne Tarquini, RN, BSN, CCRP Tarquini, RN, BSN, C", 
                    "phone": "716-845-3008"
                }, 
                "contact_backup": {
                    "email": "ASKRPCI@RoswellPark.org", 
                    "last_name": "Roswell Park", 
                    "phone": "877-275-7724"
                }, 
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263"
                    }, 
                    "name": "Roswell Park Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Tracey O'Connor, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cdillenbeck@hoacny.com", 
                    "last_name": "Coleen A Dillenbeck, MA, CCRC", 
                    "phone": "315-472-7504", 
                    "phone_ext": "1360"
                }, 
                "facility": {
                    "address": {
                        "city": "East Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13057"
                    }, 
                    "name": "Hematology-Oncology Associates of Central New York"
                }, 
                "investigator": {
                    "last_name": "Jeffrey J. Kirshner, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Jenine_Hoefler@URMC.Rochester.edu", 
                    "last_name": "Jenine Hoefler, M.S.", 
                    "phone": "585-276-3559"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "University of Rochester James P. Wilmot Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Joseph A Roscoe, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Caroline.Andrews@rochestergeneral.org", 
                    "last_name": "Caroline Andrews, MBA, CCRC", 
                    "phone": "585-922-4040"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14621"
                    }, 
                    "name": "Rochester General Hospital's Lipson Cancer and Blood Center"
                }, 
                "investigator": {
                    "last_name": "Peter Bushunow, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Alternative Approaches for Nausea Control", 
        "overall_contact": {
            "email": "Jenine_Hoefler@URMC.Rochester.edu", 
            "last_name": "Jenine Hoefler, M.S.", 
            "phone": "585.276.3559"
        }, 
        "overall_official": {
            "affiliation": "University of Rochester", 
            "last_name": "Joseph A Roscoe, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Data and Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Nausea and emesis will be measured by a patient report diary completed by patients over a five-day period.  Each day is divided into four segments (morning, afternoon, evening, night) in which patients report the severity of nausea and number of vomiting episodes for each period of the day.  Severity of nausea is assessed on a 7-point rating scale, anchored at one end by 1 = \"Not at all nauseated\" and at the other end by 7 = \"Extremely nauseated.\"  Vomiting episodes will be recorded for the same time intervals.", 
            "measure": "patient report nausea diary", 
            "safety_issue": "No", 
            "time_frame": "five days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695993"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Rochester", 
            "investigator_full_name": "Joseph Roscoe", 
            "investigator_title": "Research Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Rochester", 
        "sponsors": {
            "collaborator": {
                "agency": "National Center for Complementary and Alternative Medicine (NCCAM)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Rochester", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}